The new European guidelines for prevention of cardiovascular disease are misleading

Area of Science:

• Cardiology
• Atherosclerosis
• Endocrinology

Background:

• The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) released revised guidelines for managing chronic heart disease, blood lipids, and diabetes.
• These guidelines represent a significant update in cardiovascular and metabolic disease management.

Purpose of the Study:

• To critically evaluate the recent ESC/EAS guidelines.
• To identify and highlight studies and evidence that appear to have been overlooked or contradicted by the guideline recommendations.

Main Methods:

• A detailed review and scrutiny of the published ESC/EAS guidelines.
• Comparative analysis of guideline conclusions against existing scientific literature, particularly conflicting studies.

Main Results:

• The guideline authors appear to have ignored numerous studies conflicting with their conclusions.
• Evidence suggests LDL-cholesterol is lower in acute myocardial infarction patients, high cholesterol isn't a risk for diabetics, and coronary artery calcification isn't linked to LDL-C.
• 27 follow-up studies indicate high cholesterol levels are not associated with shorter lifespans; statin trials show limited or no reduction in cardiovascular disease or total mortality, especially in specific demographics, and are linked to adverse effects.

Conclusions:

• The current ESC/EAS guidelines may not fully reflect the totality of scientific evidence, particularly regarding cholesterol's role and statin efficacy/safety.
• There is a need for a more comprehensive consideration of all relevant research in guideline development to ensure optimal patient management and safety.